Small Stocks, Big Money

OKYO Pharma Limited (NASDAQ: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 trial of OK-101 to treat DED patients, OKYO is also evaluating OK-101 to treat NCP patients with the just announced opening of a Phase 2 trial to treat the debilitating conditions of NCP. Visit www.redchip.com/stocks/okyo to learn more. OKYO Pharma (OKYO) is a client of RedChip Companies, Inc. OKYO agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in August 2024, and 50,000 stock options with a $1 strike price and five-year expiration, for six month of investor awareness services. RedChip intends to and will, if possible, exercise and sell all of its options immediately upon eligibility, and you may be buying as RedChip is selling. OKYO also agreed to pay RedChip a one-time forty-four thousand dollar fee for a 10-day national TV ad campaign aired June 11 through June 25, 2024, a one-time twenty-thousand dollar fee for a five-day national TV ad campaign aired August 5 through August 9, 2024, a one-time thirty-eight-thousand five-hundred dollar fee for a 10-day national TV ad campaign aired October 16 through October 29, 2024, and a one-time #33,000 cash fee for a 10-day national TV ad campaign aired November 7 through November 20, 2024. Read our full disclosures at: www.redchip.com/legal/disclosures

VSee Health is a software-as-a-service (SaaS) platform that enables clinicians and enterprises to create their telehealth workflows without programming. VSee Health's system allows a telehealth mobile app to be created or a telehealth system to be integrated into existing hospital operations in days. With a focus on patient disease state telemedicine and turnkey billing services, VSee Health has integrated an intensive care, critical care and neuro solution, powered by iDoc Telehealth Solutions, as its initial module for the VSee Health software platform. This technology encompasses a set of integrated telehealth technologies and a team of neurointensivists, neurologists, and tele-radiologists that treat and coordinate care for acutely ill patients 24/7/365 in the neurointensive care unit (Neuro-ICU), cardiac surgery intensive care unit (CS-ICU) and the intensive care unit (ICU) for stroke, brain trauma and a wide range of neurological conditions. Visit www.redchip.com/stocks/VSEE to learn more. VSee Health (VSEE) is a client of RedChip Companies. VSEE agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in October 2024, for six month of investor awareness services. VSEE also agreed to pay RedChip a $50,000 fee for a national TV ad campaign aired weekdays from November 11 to November 22, 2024. VSee is a client of RedChip Companies. Read our full disclosures at: www.redchip.com/legal/disclosures

Can-Fite BioPharma is an advanced clinical stage drug development company with a platform of oral drugs designed to address multi-billion-dollar markets in the treatment of oncology and inflammatory diseases. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of NASH a Phase III trial for hepatocellular carcinoma (HCC), and the Company is planning a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. Visit www.redchip.com/stocks/canf to learn more. Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in April 2024, for four month of investor awareness services. CANF also agreed to pay RedChip one-time cash fees of fifty-thousand dollars, twenty-two thousand five hundred dollars, and forty-five thousand dollars, for two-week national TV ad campaigns aired weekdays from June 3 to June 14, 2024, June 19 to June 25, 2024, and October 2 to October 15, 2024, respectively. For full disclosure, visit RedChip.com/disclosures

The MUSQ Global Music Industry ETF (MUSQ) offers investors focused exposure to the growing global music industry. The fund aims to replicate the performance of the MUSQ Global Music Industry Index (MUSQIX), which rebalances quarterly and includes publicly traded companies and royalty funds with significant revenues tied to music. MUSQ provides access to key segments such as music streaming, live events and ticketing, content distribution, satellite and broadcast radio, and music equipment and technology. Launched in July 2023, the fund is positioned to benefit from the evolving digital landscape, including the rise of streaming and AI-driven content creation. With the global music industry projected to grow significantly in the coming years, MUSQ is an attractive vehicle for investors seeking to capture long-term growth trends in this dynamic sector. The ETF invests in companies that are integral to the modern music ecosystem, providing thematic and technology-driven exposure in a diversified, global format. Visit RedChip.com to learn more. MUSQ is a client of RedChip Companies, Inc. MUSQ agreed to pay RedChip Companies, Inc. a $5,000 monthly cash fee, beginning in August 2024, for three month of investor awareness services. MUSQ also agreed to pay RedChip a one-time $20,000 fee for a national TV ad campaign aired weekdays from October 4 to October 15, 2024, and a one-time $20,000 cash fee for a national TV ad campaign aired weekdays from November 1 to November 14, 2024. For full disclosure, visit RedChip.com/disclosures

Calidi Biotherapeutics (NYSE American:CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. Visit RedChip.com to learn more. Calidi Biotherapeutics (CLDI) is a client of RedChip Companies, Inc. CLDI agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in March 2024, and 25,000 shares of Rule 144 stock for 6 months of investor awareness services. CLDI also agreed to pay RedChip a one-time $40,000 fee for a national TV ad campaign aired weekdays from April 3 to April 17, 2024, a one-time $40,000 fee for a national TV ad campaign aired weekdays from May 28 to June 11, 2024, a one-time $40,000 fee for a national TV ad campaign aired weekdays from July 7 to August 2, 2024, a one-time $20,000 fee for a national TV ad campaign aired weekdays from August 5 to August 9, 2024, and a one-time $20,000 fee for a national TV ad campaign aired weekdays from October 16 to October 24, 2024. For full disclosure, visit RedChip.com/disclosures

Alliance Entertainment is the global leader in physical media distribution, acting as the crucial gateway between major content producers and retailers. The company partners with nearly every major film studio, music label, and video game maker, including Disney, Sony, Universal, Warner Bros., Universal Music, Sony Music, Warner Music, Microsoft, and Nintendo, to distribute their products to retailers worldwide. With over 325,000 in stock SKUs, Alliance supplies major retailers like Walmart, Amazon, and Best Buy, as well as thousands of independent stores. In fiscal 2024, Alliance generated over $1.1 billion in revenue, with more than $250 million from exclusive distribution deals. As the dominant force in the physical media market, Alliance's unmatched scale and reach secure its leadership position. Looking ahead, the company remains committed to fueling its growth through strategic acquisitions, leveraging its proven ability to expand and strengthen its portfolio in an evolving industry. Disclosure RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   Alliance Entertainment (AENT) is a client of RedChip Companies, Inc. AENT agreed to pay RedChip Companies, Inc. a $7,500 monthly cash fee, beginning in September 2024, for six month of investor awareness services. AENT also agreed to pay RedChip a one-time forty-thousand dollar fee for a 10-day national TV ad campaign aired weekdays from June 3 through June 14, 2024.   For full disclosure, visit RedChip.com/disclosures.

Nova Minerals Limited is a Gold, Antimony and Critical Minerals exploration and development company focused on advancing the Estelle Project, comprised of 514 km 2 of State of Alaska mining claims, which contains multiple mining complexes across a 35 km long mineralized corridor of over 20 advanced Gold and Antimony prospects, including two already defined multi-million ounce resources, and several drill ready Antimony prospects with massive outcropping stibnite vein systems observed at surface. The 85% owned project is located 150 km northwest of Anchorage, Alaska, USA, in the prolific Tintina Gold Belt, a province which hosts an over 220 million ounce (Moz) documented gold endowment and some of the world's largest gold mines and discoveries including, Barrick's Donlin Creek Gold Project and Kinross Gold Corporation's Fort Knox Gold Mine. The belt also hosts significant Antimony deposits and was a historical North American Antimony producer. Disclosure RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   Nova Minerals (NVA) is a client of RedChip Companies, Inc. NVA agreed to pay RedChip Companies, Inc. a $5,000 monthly cash fee, beginning in August 2024, and 600,000 shares of NVA’s ASX-listed shares, for 12 months of investor awareness services. RedChip will receive an additional 600,000 shares of NVA’s ASX-listed shares when the average five-day trading volume reaches 100,000 ADS per day or NVA’s market cap reaches $75 million within 12 months of the agreement. NVA also agreed to pay RedChip a ten-thousand dollar digital ad budget, a fifty-thousand dollar fee for a national TV ad campaign aired weekdays in August 2024, and a one-time ninety-thousand dollar cash fee for a four-week national TV ad campaign aired in October and November 2024.   For full disclosure, visit RedChip.com/disclosures.

Tracking the MUSQ Global Music Industry Index (MUSQIX), the MUSQ Global Music Industry ETF (NYSE: MUSQ) includes publicly traded companies with core interests in music streaming, content and distribution, live events, satellite and broadcast radio, and music equipment and technology. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   MUSQ is a client of RedChip Companies, Inc. MUSQ agreed to pay RedChip Companies, Inc. a $5,000 monthly cash fee, beginning in August 2024, for three month of investor awareness services. MUSQ also agreed to pay RedChip a one-time twenty-thousand dollar cash fee for a two-week national TV ad campaign aired weekdays from June 3 to June 14, 2024 and a one-time twenty-two thousand five hundred dollar cash fee for a one week national TV ad campaign.   For full disclosure, visit RedChip.com/disclosures.

ASP Isotopes harnesses two decades of research and development to produce a broad range of isotopes, serving the expanding needs of nuclear medicine and green nuclear energy sectors. The Company's cutting-edge technology positions it to meet critical global demands heightened by recent geopolitical dynamics. With cold commissioning completed at its first plant and several strategic off-take agreements in place, ASP Isotopes is on track to become a leader in non-nuclear isotope supply by 2028. Noteworthy agreements include a $27 million annual contract with BRICEM for Molybdenum-100, a $3.8 million annual deal for Carbon-14 with a Canadian firm, and a significant $9 million agreement with a U.S. customer, with initial deliveries expected in Q1 2024. Financially, the Company is well-positioned with a robust balance sheet, highlighted by no long-term debt and significant cash reserves. Despite early-stage losses, ASP Isotopes is poised for substantial revenue growth, with expectations of impactful revenue starting in the first half of 2024 as it ramps up commercial production. HC Wainwright maintains a buy rating on ASP Isotopes with a price target of $4.50 based on the Company’s advanced de-risking measures and promising revenue prospects. This robust outlook, combined with strategic expansions and innovative operational strategies, underscores ASP Isotopes' strong potential for sustained growth and value creation for its shareholders. Disclosure RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   ASP Isotopes (ASPI) agreed to pay RedChip Companies, Inc., a $12,500 monthly cash fee and $50,000 of Rule 144 stock, deemed earned immediately after the IPO, beginning in August 2022, for 12 months of RedChip investor awareness services. ASPI also agreed to pay RedChip a fifty-thousand dollar fee for a national TV ad campaign scheduled to air weekdays in May 2024.   For full disclosure, visit RedChip.com/disclosures.

OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating condition. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   OKYO Pharma (OKYO) is a client of RedChip Companies, Inc. OKYO agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in August 2024, and 50,000 stock options with a $1 strike price and five-year expiration, for six month of investor awareness services. OKYO also agreed to pay RedChip a one-time forty-four thousand dollar fee for a 10-day national TV ad campaign aired weekdays from June 11 through June 25, 2024 and a one-time twenty-thousand dollar fee for a five-day national TV ad campaign aired weekdays from August 5 through August 9, 2024.   For full disclosure, visit RedChip.com/disclosures.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company's primary focus is on its Specialized BioTherapeutics business segment, which is responsible for the development of HyBryte™ (synthetic hypericin), a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). The Company has successfully completed a Phase 3 study for HyBryte™ and has reached agreement with the European Medicines Agency (EMA) on the key design components of a confirmatory Phase 3 pivotal study while discussions with the US Food & Drug Administration remain ongoing. Additionally, Soligenix has expanded the clinical evaluation of synthetic hypericin (SGX302) into psoriasis, as well as developing proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention and treatment of gastrointestinal (GI) disorders characterized by severe inflammation. The Company is also developing a first-in-class innate defense regulator (IDR) technology, dusquetide, to treat inflammatory diseases, including oral mucositis in head and neck cancer (SGX942) and Behçet's disease (SGX945). Soligenix received FDA IND clearance in Q4 2023 for a Phase 2 trial of SGX945 (dusquetide) for the treatment of aphthous ulcers in Behçet's disease and “Fast Track” designation from the FDA in January 2024. Soligenix's Public Health Solutions business segment is responsible for the development of a number of exciting new products designed to combat a variety of severe medical conditions, including RiVax®, a ricin toxin vaccine candidate that will combat ricin poisoning, as well as vaccine programs focused on filoviruses, including Ebola (SuVax™) and Marburg (MarVax™), each of which were granted Orphan designation by the FDA in April 2024. The Company is also working on a promising vaccine candidate for the prevention of COVID-19. Soligenix is utilizing a proprietary heat stabilization platform called ThermoVax® to develop its vaccine products. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA). RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   Soligenix (SNGX) is a client of RedChip Companies, Inc. SNGX agreed to pay RedChip Companies, Inc. 50,000 shares of Rule 144 stock, deemed earned immediately, and a monthly cash fee of $10,000, beginning in April 2023, for 12 months of RedChip investor awareness services. SNGX also agreed to pay RedChip a one-time fifty-thousand dollar fee for a 10 day national TV ad campaign aired June 12 through June 25, 2024.   For full disclosure, visit RedChip.com/disclosures.

OS Therapies (OSTX), a clinical stage biopharmaceutical company, is at the forefront of developing innovative treatments for Osteosarcoma (OS), breast cancer and other solid tumors. With a dedicated focus on addressing the unmet need for new cancer treatments in children and young adults, the company is making significant strides in tackling the complexities of OS, a rare but aggressive bone cancer predominantly affecting individuals under 40 years of age. The company's primary initiative revolves around its lead product candidate, OSTHER2 (OST31-164), which is poised to revolutionize the treatment landscape for OS, breast cancer, and other HER2 expressing cancers. This innovative immunotherapy leverages a genetically modified strain of Listeria monocytogenes to specifically target cancer cells that express HER2 p, a promising approach in the fight against cancer that is complementary to HER2 antibody therapy such as Herceptin®. Notably, OST-HER2 is distinct in the current landscape, as there have been no new treatments approved by the FDA for OS in over 40 years. In addition to OST-HER2, OS Therapies is expanding its impact with the OST-Tunable Antibody Drug Conjugate (OST-tADC) platform. This cutting-edge technology represents a next-generation approach in antibody-drug conjugates (ADCs), featuring tunable pH-sensitive silicone linkers (SiLinkers™) and the potential to deliver a range of payloads, including antibodies, chemotherapeutics, and mRNA treatments. The OST-tADC platform is being developed to target solid tumors. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   OS Therapies (OSTX) is a client of RedChip Companies, Inc. OSTX agreed to pay RedChip Companies, Inc. a $15,000 monthly cash fee, beginning in August 2024, for 12 months of investor awareness services. OSTX also agreed to pay RedChip a one-time one-hundred-thousand dollar fee for a 20-day national TV ad campaign scheduled to air weekdays from June 14 through July 14, 2024.   For full disclosure, visit RedChip.com/disclosures.

American Resources Corp. (NASDAQ: AREC) is a next-generation, environmentally and socially responsible supplier of high-quality raw materials to the new infrastructure market. The Company is focused on the extraction and processing of metallurgical carbon, an essential ingredient used in steelmaking, critical and rare earth minerals for the electrification market, and reprocessed metal to be recycled. American Resources has a growing portfolio of operations located in the Central Appalachian basin of eastern Kentucky and southern West Virginia where premium quality metallurgical carbon and rare earth mineral deposits are concentrated. American Resources has established a nimble, low-cost business model centered on growth, which provides a significant opportunity to scale its portfolio of assets to meet the growing global infrastructure and electrification markets while also continuing to acquire operations and significantly reduce their legacy industry risks. Its streamlined and efficient operations are able to maximize margins while reducing costs. American Resources is monetizing its carbon assets while simultaneously capitalizing on the wealth of opportunities for the rapid growth of its ReElement Technologies division, which recently became the first domestic, commercial producer of isolated and high-purity rare-earth elements. It is estimated that approx. $3 billion worth of rare-earth elements end up in landfills annually from end-of-life products. ReElement’s patented modular platform technology enables it to process rare earths in an environmentally friendly way that avoids polluting landfills while reducing mining-based environmental impact and mitigating cross-border supply chain risk. New energy storage technologies and EVs currently depend on China, which controls 85% of the market for rare earth metals. American Resources has the capacity to change this dynamic, producing higher purity minerals with OpEx in line with Chinese producers, driving exponential growth for the Company while creating jobs in the US. American Resources generated $21.4 million revenue in the 12-months ended September 30, 2023. With strong tailwinds, a multi-pronged business strategy, and experienced management, American Resources’ revenue growth is expected to accelerate in the quarters ahead. The Company plans to spin off its ReElement and American Carbon subsidiaries in 2024. ReElement is expected to be spun off at a premium to the current overall market cap of American Resources. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   American Resources Corporation (AREC) is a client of RedChip Companies, Inc. AREC agreed to pay RedChip Companies, Inc. 50,000 Shares of Rule 144 Stock for RedChip investor awareness services, covering a term from 2021 through 2024. AREC also agreed to pay RedChip a one-time cash fee of ten-thousand dollars and fifty-thousand shares of Rule 144 stock for a national TV ad campaign aired April and May 2024.   For full disclosure, visit RedChip.com/disclosures.

GreenPower Motor Company is advancing the adoption of electric vehicles (EVs) by making all-electric buses and trucks affordable, durable and easy to deploy. GreenPower offers commercial vehicles for the movement of goods and people that are built from the ground up to be all-electric and are never converted. This “clean sheet” design ensures a safe, sustainable and sensible form of transportation, allowing for optimal placement of the battery and propulsion systems, increasing the overall vehicle strength and significantly enhancing the battery weight distribution compared to other EVs. With more than 700 GreenPower all-electric, purpose-built, zero-emission vehicles delivered, a substantial order pipeline and key partnerships across various sectors, GreenPower is poised for continued growth and market expansion. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   GreenPower Motor Company (GP) is a client of RedChip Companies, Inc. GP agreed to pay RedChip Companies, Inc. a $10,500 monthly cash fee, beginning in February 2024, for six month of investor awareness services. GP also agreed to pay RedChip a one-time twenty-thousand dollar fee for a one week national TV ad campaign aired September 2024.   For full disclosure, visit RedChip.com/disclosures. Visit RedChip.com to learn more.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   Nexalin (NXL) is a client of RedChip Companies. NXL agreed to pay RedChip a one-time forty-five-thousand dollar fee for a three-week national TV ad campaign that aired weekdays from March 21 through April 10, 2024 and a one-time forty-thousand dollar fee for a two-week national TV ad campaign airing weekdays from June 17 to July 1, 2024.   For full disclosure, visit RedChip.com/disclosures.

Biotricity is transforming the healthcare market by bridging the gap in remote monitoring and chronic care management with a focus on cardiology. Physicians and patients trust Biotricity's unparalleled standard for preventive and personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. Visit btcyinfo.com to learn more. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   Biotricity (BTCY) is a client of RedChip Companies. BTCY agreed to pay RedChip Companies a $7,500 monthly cash fee, beginning in February 2024, and 60,000 warrants, with an exercise price of $1.40 and three-year term, for 6 months of RedChip investor awareness services. BTCY also agreed to pay RedChip a one-time fifty-thousand dollar fee for a 10-day national TV ad campaign aired weekdays from April 8 through April 19, 2024 and a forty-five thousand dollar fee for a 10-day national TV ad campaign aired weekdays from June 24 through July 8, 2024.   For full disclosure, visit RedChip.com/disclosures.

bioAffinity Technologies, Inc. (NASDAQ: BIAF) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung , is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath ® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services , a subsidiary of bioAffinity Technologies. Research and optimization of the Company’s platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San Antonio. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   bioAffinity (BIAF) is a client of RedChip Companies, Inc. BIAF agreed to pay RedChip Companies, Inc. an $8,500 monthly cash fee, beginning in October 2023 , and 50,000 shares of Rule 144 stock (subject to board approval) for 12 months of investor awareness services. BIAF also agreed to pay RedChip a one-hundred-thousand dollar fee for national TV ad campaigns, aired in February and April 2024, and a thirty-thousand dollar fee for a national TV ad campaign aired in September 2024.   For full disclosure, visit RedChip.com/disclosures.

In this exclusive interview, we sit down with the CEO of Alta Global Group (MMA) to uncover how they're transforming the world of MMA training. Discover their innovative strategies to engage 640 million MMA fans worldwide. Learn about their unique business model, partnerships with legends like Conor McGregor, and their vision for the future of mixed martial arts training. Topics Covered: Overview of Alta Global Group's mission and business model Insights into partnerships with top MMA stars and coaches How they are converting fans into active participants Exclusive look into their subscription-based training programs The future of MMA training and fan engagement RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   Alta Global Group (MMA) is a client of RedChip Companies, Inc. MMA agreed to pay RedChip Companies, Inc. a $5,000 monthly cash fee, beginning in April 2024, and 15,000 shares of Rule 144 stock, for 12 months of investor awareness services. MMA also agreed to pay RedChip a fifty-thousand dollar fee for a national TV ad campaign scheduled to air weekdays in May 2024.   For full disclosure, visit RedChip.com/disclosures.

Can-Fite BioPharma is an advanced clinical stage drug development company with a platform of oral drugs designed to address multi-billion-dollar markets in the treatment of oncology and inflammatory diseases. The Company has 2 drug candidates in advanced stages of development, Piclidenoson for the treatment of psoriasis and Namodenoson for the treatment of advanced liver cancer. For each of the drugs, a registration plan has been agreed with both the U.S. FDA and the European Medicines Agency (EMA) and enrollment of patients for a pivotal Phase III clinical study is ongoing for liver cancer and underway for psoriasis. Namodenoson also has a robust anti-cancer effect against pancreatic cancer and a Phase IIa clinical study will be initiated in Q2 2024. Due to the liver-protective effect of Namodenoson, a Phase IIb study for the treatment NASH (MASH), is currently enrolling patients. Piclidenoson and Namodenoson have an excellent safety profile with experience in over 1,600 patients in clinical studies to date Visit RedChip.com to learn more. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   Can-Fite Biopharma (CANF) is a client of RedChip Companies, Inc. CANF agreed to pay RedChip Companies, Inc. a $10,000 monthly cash fee, beginning in April 2024, for four month of investor awareness services. CANF also agreed to pay RedChip one-time cash fees of fifty-thousand dollars, twenty-two thousand five hundred dollars, and forty-five thousand dollars, for two-week national TV ad campaigns aired weekdays from June 3 to June 14, 2024, June 19 to June 25, 2024, and October 2 to October 15, 2024, respectively.   For full disclosure, visit RedChip.com/disclosures.

BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI. BioVie is poised for significant catalysts in 2023, including data read out from its Alzheimer’s Phase 3 trial, expected in Q4 2023, as well as interim data read outs from the Company’s planned Phase 3 study in Parkinson’s. BioVie has multiple other efforts underway that may create additional catalysts and will be announced publicly when the Company deems appropriate. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   BioVie (BIVI) is a client of RedChip Companies, Inc. BIVI agreed to pay RedChip Companies, Inc., a $7,500 monthly cash fee, beginning in March 2022, for 12 months of RedChip investor awareness services. The CEO of RedChip Companies owns 3,150 shares of BIVI. BIVI also agreed to pay RedChip a fifty-thousand dollar fee for a national TV ad campaign scheduled to air weekdays from June 17 through July 1, 2024.   For full disclosure, visit RedChip.com/disclosures.